Can You Get Pregnant on Tamoxifen?

Tamoxifen does not prevent pregnancy. In fact, it can increase your chances of conceiving because of how it interacts with your body’s reproductive hormones. This makes tamoxifen a paradox: it is prescribed to millions of women as a breast cancer treatment, yet it works on the same biological pathway that fertility doctors exploit to help people get pregnant. The practical implications depend entirely on your situation and why you are taking the drug.

How Tamoxifen Triggers Ovulation

Tamoxifen is a selective estrogen receptor modulator, meaning it blocks estrogen in some tissues (like breast tissue) while mimicking estrogen in others. In the brain, tamoxifen blocks estrogen receptors in the hypothalamus and pituitary gland. Your brain reads this blockade as a sign that estrogen levels are low, so it responds by ramping up production of the hormones that drive ovulation. Studies measuring hormone levels in women on tamoxifen show that follicle-stimulating hormone and luteinizing hormone both rise during or shortly after tamoxifen use, followed by a gradual climb in estradiol that can reach an extremely high preovulatory peak, triggering an LH surge and ovulation.¹

This is the same trick that clomiphene citrate (Clomid) uses to induce ovulation. Both drugs fool the brain into thinking estrogen is scarce, which jumpstarts the ovulatory cascade. If you are premenopausal and still cycling, tamoxifen will not suppress your fertility. It will likely enhance it. That is why oncologists insist on reliable contraception for premenopausal breast cancer patients taking the drug.

Tamoxifen as a Deliberate Fertility Treatment

Reproductive endocrinologists sometimes prescribe tamoxifen specifically to induce ovulation in women who are not ovulating on their own, particularly those with polycystic ovary syndrome (PCOS). In one study of 240 women with ovulatory dysfunction, pregnancy rates ranged from about 14% at a lower dose of tamoxifen to 40% at a higher dose, and among the PCOS subgroup, roughly 39% became pregnant.² A separate head-to-head trial found tamoxifen and clomiphene citrate equally effective at inducing ovulation and achieving pregnancy in women with PCOS.³

One comparison of clomiphene, tamoxifen, and letrozole in women with isolated anovulation found pregnancy rates of 64%, 40%, and 50% respectively, but tamoxifen stood out for having a lower miscarriage rate: 6% compared to 20% with clomiphene.⁴ This lower miscarriage rate may relate to tamoxifen’s effects on the uterine lining, which we will come back to. The point is clear: tamoxifen is not just capable of enabling pregnancy, it is deliberately used for that purpose in fertility clinics.

Why Getting Pregnant While on Tamoxifen for Breast Cancer Is Dangerous

If tamoxifen promotes fertility, why do oncologists tell you not to get pregnant on it? Because tamoxifen and its breakdown products interact with developing embryonic and fetal tissues, and the evidence on birth defects is concerning enough that it is classified as a Pregnancy Category D drug. A review of the manufacturer’s safety records documented 16 live births with congenital malformations and 122 without malformations among women who were taking tamoxifen during pregnancy. While the majority of exposed pregnancies resulted in healthy births, the relatively high frequency of severe congenital abnormalities led the authors to conclude that reliable birth control during tamoxifen treatment is mandatory.⁵

A separate analysis estimated that unexpected tamoxifen use during pregnancy could cause adverse outcomes in roughly a quarter to a third of cases, including preterm labor, spontaneous abortion, stillbirth, and congenital malformations, especially of the urogenital tract.⁶ And because tamoxifen has a long half-life and its active metabolites linger in the body for weeks, the risk does not vanish the moment you stop taking it. Most oncologists recommend waiting at least two to three months after stopping tamoxifen before attempting conception, to allow the drug and its metabolites to clear.

That said, accidental pregnancies on tamoxifen do happen, and they do not always end badly. Case reports describe women who conceived on tamoxifen, stopped the drug, and delivered healthy babies at term.⁶ The full scope of risk, including whether tamoxifen exposure could cause subtler problems that only appear later in the child’s development, remains unknown.⁷ This uncertainty is exactly why the medical guidance is firm: do not plan a pregnancy while actively taking tamoxifen.

Contraception Options If You Are Taking Tamoxifen

Because tamoxifen boosts ovulation rather than suppressing it, the contraception question for breast cancer patients on tamoxifen is not optional. But it is also not straightforward, because most hormonal contraceptives are off the table for women with hormone-receptor-positive breast cancer. Estrogen-containing methods like the combined pill, patch, and ring are contraindicated. Even progestin-only options are generally avoided due to theoretical concerns about hormonal stimulation of residual cancer cells.

The copper intrauterine device (Cu-IUD) is widely considered the first-line choice. It is hormone-free, highly effective, long-acting, and reversible. The evidence supporting its use in women with a history of breast cancer is strong.⁸ Barrier methods like condoms are another non-hormonal option, though they have higher typical-use failure rates.

There is one notable exception to the “no hormonal methods” rule. The levonorgestrel-releasing intrauterine system (LNG-IUS, sold under brand names like Mirena) is sometimes considered for women specifically on tamoxifen, because tamoxifen has estrogenic effects on the uterine lining that can lead to endometrial thickening, polyps, and in rare cases, endometrial cancer. The LNG-IUS protects the endometrium by delivering a small dose of progestin directly to the uterus.⁹ The evidence for this approach is classified as less robust than for the copper IUD, but it has not been shown to increase tumor recurrence.⁸ This is a decision best made with your oncologist and gynecologist together, weighing your endometrial risk against the theoretical hormonal exposure.

Pausing Tamoxifen to Get Pregnant Safely

For years, young women diagnosed with hormone-receptor-positive breast cancer faced a painful either/or: finish the full five to ten years of endocrine therapy and accept that your fertility window may close, or stop treatment early and risk your cancer returning. A landmark trial called POSITIVE changed that conversation. The trial enrolled premenopausal women who had been on endocrine therapy (tamoxifen, an aromatase inhibitor, or both) for 18 to 30 months and allowed them to pause treatment for up to two years to attempt pregnancy.

Among nearly 500 women followed for pregnancy outcomes, about 74% achieved at least one pregnancy and roughly 64% had at least one live birth. After a median follow-up of about 41 months, the rate of breast cancer events in the treatment-interruption group was not meaningfully different from a matched control group that had not paused therapy.¹⁰ Longer follow-up data confirmed these findings. After a median of about six years, roughly 76% had achieved pregnancy and 69% had at least one live birth. The five-year rate of breast cancer events was comparable between the interruption group and control cohorts, and pregnancy itself did not worsen outcomes.¹¹

A separate study with even longer follow-up (a median of 8.5 years) found that women who interrupted tamoxifen for pregnancy actually had lower recurrence risk than controls, likely reflecting selection bias (healthier, lower-risk patients are more likely to pursue pregnancy) rather than a protective effect of pregnancy itself.¹² Still, the reassurance is meaningful: pausing tamoxifen for pregnancy does not appear to create a dangerous gap in cancer protection, at least through the first several years of follow-up.

Age matters, though. Among POSITIVE participants, 86% of women under 35 conceived, compared with 76% of those aged 35 to 39 and 53% of those 40 to 42.¹¹ These rates roughly mirror what is seen in the general population of the same age. Time to conception also increased with age, so the earlier you can have this conversation with your oncologist, the more options you are likely to have.

Fertility Preservation Before Starting Cancer Treatment

For women who are about to begin chemotherapy or long-term endocrine therapy, freezing eggs or embryos before treatment starts is a well-established fertility preservation strategy. The standard approach involves stimulating the ovaries with injectable hormones to produce multiple eggs, but for breast cancer patients, the resulting spike in estradiol can be a concern since elevated estrogen might fuel hormone-receptor-positive tumors.

This is where tamoxifen plays yet another role. Used alongside FSH injections during ovarian stimulation, tamoxifen blocks the estrogen receptors that matter for cancer growth while still allowing enough ovarian response to retrieve a useful number of eggs. Stimulation protocols using tamoxifen or aromatase inhibitors produce lower estradiol peaks while yielding a similar number of oocytes and embryos as standard protocols.¹³ A recent comparison of letrozole and tamoxifen as co-treatments during fertility preservation found similar numbers of retrieved and cryopreserved oocytes and embryos with either drug.¹⁴

Early work on tamoxifen-based IVF in breast cancer patients showed it produced embryos in every patient treated, whereas natural-cycle IVF generated embryos in only three out of five patients, and cycle cancellation was much less common with the tamoxifen protocol.¹⁵ Today, letrozole has become more widely used for this purpose in many centers, but tamoxifen remains a valid option, especially when letrozole is unavailable or when a patient’s oncologist prefers it for a specific clinical reason.

Does Tamoxifen Damage Your Ovarian Reserve?

Women who take tamoxifen for breast cancer often worry that the drug itself might deplete their egg supply. Chemotherapy is well known for causing significant, sometimes permanent, ovarian damage. Tamoxifen, however, does not appear to share this effect. A study tracking anti-Müllerian hormone (AMH), a marker of ovarian reserve, found that tamoxifen-only treatment did not significantly alter age-adjusted AMH levels over 24 months. Any small decline observed was consistent with what would be expected from normal aging. In contrast, women who received chemotherapy showed far greater AMH declines over the same period.¹⁶

This is reassuring if your treatment plan includes tamoxifen without chemotherapy. If you had chemotherapy first and then moved to tamoxifen, the ovarian damage was caused by the chemotherapy, not the tamoxifen phase. Either way, the tamoxifen years are not silently eroding your remaining egg supply. The bigger enemy is time: the longer your endocrine therapy lasts, the older you are when you finish, and age is the most powerful driver of declining fertility.

When the Male Partner Takes Tamoxifen

Tamoxifen is not only a women’s medication. Urologists and reproductive endocrinologists sometimes prescribe it off-label to men with low sperm counts. The mechanism is similar to what happens in women: tamoxifen blocks estrogen receptors in the hypothalamus, prompting the brain to produce more FSH and LH, which in men stimulates the testes to produce more testosterone and more sperm.

In a randomized trial of men with idiopathic low sperm counts, those who received tamoxifen plus testosterone undecanoate roughly doubled their median total sperm count over six months. Progressive motility and normal morphology also improved. The spontaneous pregnancy rate was about 34% in the treatment group compared to 10% in the placebo group, roughly a threefold increase in the odds of conceiving.¹⁷ A systematic review noted that the evidence across tamoxifen studies in men is heterogeneous and a formal meta-analysis of pregnancy rates could not be calculated, so the data on male tamoxifen and pregnancy remains somewhat patchy.¹⁸ Still, the direction of evidence is consistent: tamoxifen can improve sperm parameters in men with otherwise unexplained subfertility.

Tamoxifen and the Uterine Lining

One of the more unexpected fertility applications of tamoxifen involves women who have a persistently thin endometrium, the uterine lining that a fertilized embryo implants into. A lining that is too thin can make implantation difficult, leading to failed embryo transfers. Tamoxifen’s mixed estrogen-agonist/antagonist activity seems to boost endometrial growth in women whose lining does not respond well to standard hormone replacement.

A study of women with thin endometrium undergoing frozen embryo transfer found that adding tamoxifen significantly increased lining thickness across different treatment backgrounds, from roughly 6 mm to about 8 mm on average. Among the subgroup with PCOS, the results were particularly striking: the endometrium reached an average thickness of about 9.3 mm, and the clinical pregnancy rate reached 60% per transfer.¹⁹ A meta-analysis pooling several studies confirmed that tamoxifen improved endometrial thickness compared to standard hormone replacement, though it could not show a clear advantage in clinical pregnancy rates or implantation rates over other approaches like letrozole-based protocols.²⁰

This is a niche use, but it illustrates just how versatile tamoxifen’s reproductive effects are. It can trigger ovulation, thicken a reluctant uterine lining, and improve sperm quality in men. The same drug that breast cancer patients are told will require strict contraception is being used down the hall in the fertility clinic to help people conceive.

Tamoxifen and Breastfeeding

Some women who become pregnant after breast cancer treatment want to breastfeed and then resume tamoxifen, or they face the question of whether tamoxifen can be taken while nursing. The data here is extremely limited. A first-of-its-kind pharmacokinetic study measured tamoxifen and its active metabolites in the breast milk of a lactating mother. Tamoxifen concentrations in milk rose over time, and the two clinically important metabolites, 4-hydroxy-tamoxifen and endoxifen, reached levels considered clinically significant by about 18 days after the mother started taking the drug.²¹

Because tamoxifen and its active metabolites pass into breast milk at potentially meaningful concentrations, breastfeeding while taking tamoxifen is generally not recommended. The effects of these metabolites on a developing infant are unknown. Most guidelines advise completing breastfeeding before restarting tamoxifen, though the decision about how long to breastfeed before resuming cancer therapy is one where oncologists and patients weigh competing priorities on a case-by-case basis.

1
PubMed. Endocrine profiles in tamoxifen-induced ovulatory cycles
2
PubMed Central. Tamoxifen: An alternative to clomiphene in women with polycystic ovary syndrome
3
PubMed Central. Comparison of Tamoxifen and Clomiphene Citrate for Ovulation Induction in Women with Polycystic Ovarian Syndrome: A Prospective Study
4
PubMed Central. Comparison of the effectiveness of clomiphene citrate, tamoxifen and letrozole in ovulation induction in infertility due to isolated unovulation
5
PubMed Central. Use of tamoxifen before and during pregnancy
6
PubMed Central. Tamoxifen exposure in pregnancy after synchronous breast and thyroid cancer
7
PubMed. Tamoxifen and pregnancy
8
Medical Research Archives. Hormonal Contraception in Breast Cancer Survivors: From Hormonal Physiology to Future Perspectives
9
PubMed Central. Contraception for cancer survivors
10
PubMed. Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer
11
PubMed Central. Achieving Pregnancy After Early Hormone Receptor-Positive Breast Cancer: Recent Evidence and Clinical Considerations
12
PubMed Central. Impact of the interruption of tamoxifen for pregnancy on the recurrence and survival outcomes among young women with breast cancer
13
PubMed Central. Fertility preservation in women with breast cancer
14
PubMed. Letrozole or tamoxifen co-administration during fertility preservation for patients affected by breast cancer
15
Human Reproduction. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen
16
PubMed Central. Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer
17
Fertility and Sterility. Effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in men with idiopathic oligozoospermia
18
PubMed Central. Efficacy of clomiphene citrate and tamoxifen on pregnancy rates in idiopathic male subfertility: A systematic review and meta-analysis
19
PubMed. The Effect of Tamoxifen on Thin Endometrium in Patients Undergoing Frozen-Thawed Embryo Transfer
20
Clinical and Experimental Obstetrics & Gynecology. Efficacy of tamoxifen for infertile women with thin endometrium undergoing frozen embryo transfer: a meta-analysis
21
PubMed Central. First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother: a case study